Liposomal cyclosporine. Characterization of drug incorporation and interbilayer exchange
- PMID: 7491708
Liposomal cyclosporine. Characterization of drug incorporation and interbilayer exchange
Abstract
A number of previous studies have examined the application of liposomes as carriers for the immunosuppressive agent cyclosporine. These studies, however, have generated equivocal results, particularly with regard to the therapeutic properties of such systems. In the present work, we have characterized cyclosporine incorporation into well defined liposomes, large unilamellar vesicles, and have examined the stability of drug association. Contrary to some earlier reports, we show that only modest levels of cyclosporine can be accommodated in the liposomal membrane and that the extent of drug incorporation is greatly reduced as the bilayer cholesterol content is increased. Furthermore, we demonstrate that cyclosporine, despite its hydrophobic character, can rapidly exchange between vesicles. This raises the possibility that, after i.v. administration, drug migration to other blood components might negate the potential benefits arising from liposomal delivery. In a companion paper, therefore (Choice et al., Transplantation, 1995, this issue), we have followed the pharmacokinetics and biodistribution of liposomal cyclosporine in a study that examined the behavior of both the drug and the liposomal carrier.
Similar articles
-
Liposomal cyclosporine. Comparison of drug and lipid carrier pharmacokinetics and biodistribution.Transplantation. 1995 Nov 15;60(9):1006-11. Transplantation. 1995. PMID: 7491673
-
Preparation, characterisation and biodistribution of 99mTc-labeled liposome encapsulated cyclosporine.J Drug Target. 2003 Apr;11(3):187-96. doi: 10.1080/10611860310001615415. J Drug Target. 2003. PMID: 13129826
-
Tamoxifen in topical liposomes: development, characterization and in-vitro evaluation.J Pharm Pharm Sci. 2004 Jul 16;7(2):252-9. J Pharm Pharm Sci. 2004. PMID: 15367383
-
Liposomal formulations of Cyclosporin A: a biophysical approach to pharmacokinetics and pharmacodynamics.Crit Rev Ther Drug Carrier Syst. 2001;18(2):141-72. Crit Rev Ther Drug Carrier Syst. 2001. PMID: 11325030 Review.
-
Transfer of lipophilic drugs between liposomal membranes and biological interfaces: consequences for drug delivery.Eur J Pharm Sci. 2005 Nov;26(3-4):251-65. doi: 10.1016/j.ejps.2005.05.012. Eur J Pharm Sci. 2005. PMID: 16112849 Review.
Cited by
-
Oral cyclosporine A--the current picture of its liposomal and other delivery systems.Cell Mol Biol Lett. 2009;14(1):139-52. doi: 10.2478/s11658-008-0041-6. Epub 2008 Nov 12. Cell Mol Biol Lett. 2009. PMID: 19005620 Free PMC article. Review.
-
Nanoparticle delivery systems for substance use disorder.Neuropsychopharmacology. 2022 Jul;47(8):1431-1439. doi: 10.1038/s41386-022-01311-7. Epub 2022 Mar 28. Neuropsychopharmacology. 2022. PMID: 35351961 Free PMC article. Review.
-
A comparison of step-gradient and sequential density ultracentrifugation and the use of lipoprotein deficient plasma controls in determining the plasma lipoprotein distribution of lipid-associated nystatin and cyclosporine.Pharm Res. 1999 Jan;16(1):165-9. doi: 10.1023/a:1011951602894. Pharm Res. 1999. PMID: 9950297 No abstract available.
-
Linoleic Acid-Based Transferosomes for Topical Ocular Delivery of Cyclosporine A.Pharmaceutics. 2022 Aug 15;14(8):1695. doi: 10.3390/pharmaceutics14081695. Pharmaceutics. 2022. PMID: 36015321 Free PMC article.
-
Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases.Int J Nanomedicine. 2008;3(1):1-19. Int J Nanomedicine. 2008. PMID: 18488412 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources